Efficacy of biologic therapy on airway hyperresponsiveness in asthma

Rory Chan, Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journalReview articlepeer-review


Airway hyperresponsiveness refers to an exaggerated bronchial constrictor response to a given exogenous inhaled agent and is governed by airway smooth muscle along with mucosal inflammation in asthma. In recent years, the advent of biologics and antialarmins has transformed severe asthma treatment in terms of reducing oral-corticosteroid–requiring exacerbations and improving disease control, asthma quality of life, and spirometry-measured lung function. In contrast, there have been comparatively fewer studies investigating the efficacy of biologics in airway hyperresponsiveness. In this focused review, we summarize the existing evidence base in this area regarding omalizumab, mepolizumab, benralizumab, and tezepelumab.

Original languageEnglish
Number of pages12
JournalAnnals of Allergy, Asthma and Immunology
Early online date22 Feb 2023
Publication statusE-pub ahead of print - 22 Feb 2023


  • omalizumab
  • mepolizumab
  • dupilumab
  • airway hyperresponsiveness
  • tralokinumab
  • benralizumab
  • tezepelumab

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Efficacy of biologic therapy on airway hyperresponsiveness in asthma'. Together they form a unique fingerprint.

Cite this